E1631
β-雌二醇 17-戊酸酯
≥98% (HPLC), powder
别名:
1,3,5(10)-雌三烯-3,17β-二醇 17-戊酸酯
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C23H32O3
化学文摘社编号:
分子量:
356.50
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
213-559-2
MDL number:
Beilstein/REAXYS Number:
2480357
产品名称
β-雌二醇 17-戊酸酯, ≥98%
InChI key
RSEPBGGWRJCQGY-UHFFFAOYSA-N
InChI
1S/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3
SMILES string
CCCCC(=O)OC1CCC2C3CCc4cc(O)ccc4C3CCC12C
biological source
synthetic
assay
≥98%
form
powder
technique(s)
ELISA: suitable
solubility
acetone: 25 mg/mL, hazy, colorless
shipped in
ambient
storage temp.
room temp
Quality Level
General description
β-Estradiol 17-valerate is a synthetic estrogen.
Application
β-Estradiol 17-valerate has been used:
- in an in-vivo assay, to synchronize the estrus cycle in athymic nude mice, to study the effect of recombinant pigment epithelium-derived factor (rPEDF) on induced ectopic fibroid lesions
- to study the influence of ovarian hormones on type II cGMP-dependent protein kinase (Prkg2) expression in mice
- to induce growth of estrogen-dependent tumor cells in athymic nude mice to establish a breast cancer mouse model
Biochem/physiol Actions
Estradiol valerate is observed to be useful for treating menopausal climacteric symptoms. β-Estradiol 17-valerate is used as a source of 17β-estradiol (E2) in in vitro fertilization, hormone replacement therapy, contraceptive drugs, to study reproductive disorders in animal models. It serves as growth promoter in animal farming. β-Estradiol 17-valerate is also used to culture single-sex population among fish. Studies in rats show that β-Estradiol 17-valerate has negative effects on the estrus cycle pattern.
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
ppe
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
法规信息
新产品
此项目有
Kevin Hollevoet et al.
Oncotarget, 9(17), 13623-13636 (2018-03-24)
Antibody gene transfer presents an appealing alternative to conventional antibody protein therapy. This pre-clinical study evaluates the impact of various parameters on the pharmacokinetics and efficacy of in vivo expressed DNA-based anti-HER2 monoclonal antibodies (mAbs), newly engineered and delivered via
Christophe Blockeel et al.
Reproductive biomedicine online, 24(3), 272-280 (2012-02-03)
This randomized controlled trial analyses the ability to control the oocyte retrieval schedule of gonadotrophin-releasing hormone antagonist cycles through the administration of oestradiol valerate during the luteo-follicular transition period prior to the initiation of ovarian stimulation. Eighty-six women undergoing ovarian
Huib A A M Van Vliet et al.
The Cochrane database of systematic reviews, (11)(11), CD009038-CD009038 (2011-11-11)
Quadriphasic oral contraceptives have been developed to reduce the adverse effects of oral contraceptives and are presented as more physiological since they mimic the natural cycle. However, suggested disadvantages of quadriphasic oral contraceptives include a possible increased risk of pill-taking
Elizabeth Micks et al.
Women's health (London, England), 7(5), 513-524 (2011-09-02)
Estradiol valerate and dienogest have been combined to create a novel four-phasic oral contraceptive pill effective for both pregnancy prevention and treatment of heavy menstrual bleeding. This formulation represents the only oral contraceptive pill available in the USA containing an
Gonzalo Cruz et al.
Fertility and sterility, 98(5), 1283-1290 (2012-08-03)
To investigate the developmental window in which E(2) exposure produces irreversible changes in ovarian function resulting in polycystic ovary. Basic experimental study. University animal laboratory. Thirty Sprague-Dawley rats were administered a single E(2) valerate dose (10 mg/kg of weight) at
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持